摘要
目的:探讨MA方案对成人急性髓细胞性白血病患者的疗效。方法:MA方案[米托蒽醌6￣8mg/(m2·d)静脉滴注,第1￣3天;阿糖胞苷100￣150mg/(m2·d),分2次静脉滴注,第1￣7天]治疗20例。DA方案[柔红霉素40￣50mg/(m2·d)静脉滴注,第1￣3天;阿糖胞苷同MA中用法]治疗22例,均进行2个疗程以上方可比较分析。结果:MA和DA方案总的CR率分别为:85%和68.2%,两组间比较有显著性差异(P<0.05);毒副反应为骨髓抑制明显,MA组强于DA组(P<0.05〉。结论:MA方案作为一线诱导治疗成人急性髓细胞性白血病是有效的。
Objective：To investigate the effects of MA on acute myeloid leukemia （AML）.Methods：MA [Mitoxantrone, 6-8 mg/（m^2·d）, iv drip, d1-d3;Cytarabine,100-150 mg/（m^2·d）, iv drip, d1-d7]for 20 cases, DA [Daunorubicin, 40-50 mg/（m^2·d）,iv drip,d1-d3;Cytarabine, 100-150 mg/（m^2·d）,iv drip, d1-d7] for 22 cases.Each method was applied more than twice on one case,and the clinical results were analyzed.Results：CR rate in MA group and DA group was 85%, 68.2%, respectively.The difference between them was significant （P〈0.05）. Bone marrow suppression in MA group was stronger than DA group （P〈0.05）.But side-effects were not serious in all.Conclusion ：MA was effective as first-line induction therapy for AML.
出处
《中国医药导报》
CAS
2007年第01X期32-33,共2页
China Medical Herald
